Skip to main content

EDITORIAL article

Front. Physiol., 19 April 2023
Sec. Integrative Physiology
This article is part of the Research Topic Zebrafish as a Translational Neuroscience Model: Today’s Science and Tomorrow’s Success View all 5 articles

Editorial: Zebrafish as a translational neuroscience model: today’s science and tomorrow’s success

  • 1Basic Medical Science Department, Kulliyyah of Medicine, International Islamic University Malaysia, Kuantan, Pahang, Malaysia
  • 2Department of Biology, University of Ottawa, Ottawa, ON, Canada

Zebrafish as a promising neuroscience model

One of the most significant developments in modern science is the rise of translational medicine. Danio rerio has offered a new venue for important studies, especially in the field of neurodevelopmental research. Benefits have been shown in the treatment of many neurodegenerative disorders, including Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease. Zebrafish have made molecular investigations, especially the omics, feasible in a manner that was previously impossible using other animal models, such as primates or rats, because of their translucent embryos, amenability to genetic modifications, and short generation time. Nowadays, zebrafish serve as a great model to analyse neurobehavioral traits that are relevant to humans. The fields of biology, neurology, pharmacology, and toxicology all make use of it.

The world of model organisms has increasingly acquired interest in this small tropical vertebrate species. Zebrafish have further general strengths: economic efficiency, high fertility. These characteristics have given researchers an unparalleled vertebrate experimental system with a capacity for live biological imaging and genetic and drug screening. Zebrafish were used in neuroscience and developmental genetics because of their high levels of genetic, anatomical, and physiological resemblance with humans. They have also been used to study human diseases. In 2013, the publication of the Zebrafish reference genome accelerated disease modeling in this organism. More than 80% of the disease-causing human proteins have an ortholog in zebrafish. Furthermore, new therapeutic targets and molecules were identified or discovered using zebrafish that are now being considered for human trials or are waiting for clinical application. Nevertheless, more zebrafish models are needed to broaden our understanding of human diseases. This Research Topic offers updated insights from researchers from around the world on zebrafish as a model of translational neuroscience research. While the zebrafish brain and the human brain are noticeably different in size and shape from one another, they share a very comparable organisational structure. Several regions of the zebrafish brain seem to be connected to and are often remarkably conserved when compared to their human counterparts. The ventral telencephalon of zebrafish, for instance, is thought to be similar to the human striatum. Moreover, zebrafish traits and behaviours may serve as useful models for human behaviour and development. The movement deficits seen in zebrafish exposed to neurotoxins are highly predictive of the bradykinesia seen by people with Parkinson’s disease (Hughes et al., 2020).

Genetic analyses have shown that there is 70% sequence similarity between the zebrafish and human genomes (Shehwana and Konu, 2019), with 80% of the genes positioned on the same chromosomes and in the same orders (Howe et al., 2013). Transgenic models in zebrafish are well-documented, and their genetics have been extensively studied (Kalueff and Cachat, 2011). Furthermore, the zebrafish is a unique model since its embryos grow externally and are transparent, allowing researchers to see their progress in real time as they occur (Rahman Khan and Sulaiman Alhewairini, 2019).

In this Research Topic, Pakdaman et al. examined the effects of impaired CHIP ubiquitin ligase activity in zebrafish (D. rerio). They characterized the zebrafish stub1 gene and Chip protein, generated and characterized a zebrafish mutant causing truncation of the Chip functional U-box domain. Mutant fish had decreased total 26S proteasome activity in the brain and showed behavioral changes. They concluded that truncation of the Chip U-box domain leads to impaired ubiquitin ligase activity, resulting inbehavioral and anatomical changes in zebrafish. This illustrates the potential of zebrafish to study STUB1-mediated diseases. Similarly, Heylen et al. tried to understand the mechanistic processes underlying the changes of brain tissue and networks toward increased seizure susceptibility using zebrafish larvae. They administred kainic acid (KA) by pericardial injection at an early zebrafish larval stage. Then the epileptic phenotype induced was examined by quantification of seizure-like behavior using automated video recording. Epileptiform brain activity was measured via local field potential (LFP) recordings. They found that KA induced a massive damage and inflammation in the zebrafish brain and seizure-like locomotor behavior. They described a chemically-induced larval zebrafish epilepsy model offering unique insights into studying epileptogenic processes in vivo and suitable for high-throughput Anti-epileptic drugs (AEDs) screening purposes and rapid genetic investigations. Further, Martin et al. worked on the larval ZF and they used Single-Cell RNA Sequencing to characterize the Molecular Heterogeneity of the Larval Zebrafish Optic Tectum (OT). They concluded that the larval zebrafish OT is a complex structure containing at least 25 transcriptionally distinct cell populations. This is the first time scRNA-seq has been applied to explore the OT alone and in depth. Finally, this current SI includes a narrative review by Singh and Patten that is highlighted the modeling neuromuscular diseases in zebrafish. They described the generation of different zebrafish genetic models mimicking NMDs and how they are used for drug discovery and therapy development. They recommended that optogenetic approaches to modulate subcellular expression and structure of molecules in vivo in zebrafish larvae can lead to the discovery of novel pathways, mechanistic links and new therapeutic interventions. New zebrafish models are continuously developed to study the development, progression and severity of common and rare NMDs, which can be further used for targeted gene therapy and drug discovery.

In the current Research Topic, we highlighted the use of zebrafish as a model for the evaluation of potential new treatments for neurological illnesses. Key morphological, physiological, and biochemical abnormalities in certain classes of neurons are triggered by the gene knockdown of orthologous zebrafish or transgenic expression of pathogenic genes related with human neurodegenerative illnesses. This points to a high degree of functional conservation between human genes associated with neurodegenerative diseases and their zebrafish orthologs. Hence, zebrafish may serve as a useful alternative model for understanding the molecular basis of PD. Considering the zebrafish’s unique traits, we anticipate a rise in its popularity as a high-throughput drug-screening vertebrate platform. In line with the idea of precision medicine, having a thorough understanding of the omics (genomics, proteomics, and metabolomics) of an illness might aid healthcare professionals in personalising treatment plans. To this end, zebrafish have been and will continue to be one of the gold standards of neuroscience models, particularly for projects requiring molecular research.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Acknowledgments

We sincerely acknowledge all the authors for their articles and the reviewers who have contributed to improving and clarifying these diverse contributions due to their valuable comments. Finally, we thank the Specialty Chief Editors and the Frontiers in Physiology of for their continuous support.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

Howe, K., Clark, M. D., Torroja, C. F., Torrance, J., Berthelot, C., Muffato, M., et al. (2013). The zebrafish reference genome sequence and its relationship tothe human genome. Nature 496, 498–503. doi:10.1038/nature12111

PubMed Abstract | CrossRef Full Text | Google Scholar

Hughes, G. L., Lones, M. A., Bedder, M., Currie, P. D., Smith, S. L., and Pownall, M. E. (2020). Machine learning discriminates a movement disorder in azebrafish model of Parkinson’s disease. Dis. Models Mech. 13, dmm045815. doi:10.1242/dmm.045815

PubMed Abstract | CrossRef Full Text | Google Scholar

Kalueff, A. V., and Cachat, J. M. (2011). Zebrafish models in neurobehavioralresearch. New York, NY, USA: Humana Press.

Google Scholar

Rahman Khan, F., and Sulaiman Alhewairini, S. (2019). Zebrafish (Danio rerio)as a model organism. Curr. Trends Cancer Manag., 81517. doi:10.5772/intechopen.81517

CrossRef Full Text | Google Scholar

Shehwana, H., and Konu, O. (2019). Comparative transcriptomics BetweenZebrafish and mammals: A roadmap for discovery of conserved and UniqueSignaling pathways in Physiology and disease. Front. Cell Dev. Biol. 7, 00005. doi:10.3389/fcell.2019.00005

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: zebrafish, translational, neuroscience, model, science

Citation: Mohamed WMY and Ekker M (2023) Editorial: Zebrafish as a translational neuroscience model: today’s science and tomorrow’s success. Front. Physiol. 14:1202198. doi: 10.3389/fphys.2023.1202198

Received: 07 April 2023; Accepted: 14 April 2023;
Published: 19 April 2023.

Edited and reviewed by:

Geoffrey A. Head, Baker Heart and Diabetes Institute, Australia

Copyright © 2023 Mohamed and Ekker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Wael M. Y. Mohamed, wmy107@gmail.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.